### OLIGODEOXYNUCLEOTIDE Xol26

## OLIGODEOXYNUCLEOTIDE Xol27





Figure 1






Figure 3




Figure 4




Figure 5




Figure 6





Figure 7

#### Pl. VⅢ/41



## Pl. IX/41

	ValPhe	LeuGlyMetP	heLeuTyrGl	uTyrAlaArg	ArgHisProA	spTyrSerVa	lValLeuLeu	LeuArgLeu
105	(1	1061	TTTTGTATGA 1071	ATATGCAAGA 1081	AGGCATCCTG 1091			
10.	, _	1001	1071	1001	1091	1101	1111	1121
	AlaLvs	ThrTvrGluT	hrThrLeuGl	nT.vsCvsCvs		coprovicci	11C110Th1-31	7=11= 1 Db
	GCCAAG	ACATATGAAA	CCACTCTAGA	GAAGTGCTGT	GCCGCTGCAG	SPFIORISGI STCCTCSTGS	ATGCTATCCC	TASASTENS
112	6	1136	1146	1156	1166	1176	1186	1196
						11/0	1100	1130
	AspGlu	PheLysProL	euValGluGl	uProGlnAsni	LeuIleLvsG	lnAsnCvsGl	uLeuPheGlu	GintenGlo
	GATGAA	TTTAAACCTC	TTGTGGAAGA	GCCTCAGAAT	TTAATCAAAC	AAAATTGTGA	GCTTTTTGAG	CACCTTGGA
120	1	1211	1221	1231	1241	1251	1261	1271
								<b>-</b>
	GluTyr:	LysPheGlnA	snAlaLeuLe	uValArgTyr'	ThrLysLysV	alProGlnVa	lSerThrPro	ThrLeuVal
	GAGTAC	AAATTCCAGA	ATGCGCTATT	AGTTCGTTAC	accaagaaag'	TACCCCAAGT	GTCAACTCCA	ACTCTTGTA
127	6	1286	1296	1306	1316	1326	1336	1346
	GluVal:	SerArgAsnL	euGlyLysVa	lGlySerLys	CysCysLysH	isProGluAl	aLysArgMet	ProCysAla
	GAGGTC	rcaagaaacc	TAGGAAAAGT	GGGCAGCAAA!	IGTTGTAAAC.	ATCCTGAAGC	AAAAAGAATG	CCCTGTGCA
135	1	1361	1371	1381	1391	1401	1411	1421
	C13	T	-117-17	- 61 - 7 6				
	GIUASP:	TALTENZELA	alValLeuAsı	ucrurenchs,	ValleuH1sG	LuLysThrPr	oValSerAsp.	ArgValThr
142		1436	TGGTCCTGAA					
142	0	1430	1446	1456	1466	1476	1486	1496
	TueCue	TueThrClus	erLeuValAsı	, 3 = ~3 = ~D= ~		1 - 7 1 1		
	DYSCYS	recacaeaam	CCTTGGTGAA	CACCCCACCA	rcommesera.	rarenerava	IASPGIUTNY	Tyrvalpro
150	nnic. 1	1511	1521		16C1111CAG	TEST	CGATGAAACA	
-50	•	-7	1721	1001	1741	1331	1201	1571
	LvsGlui	PheAsnAlaG	luThrPheTh	rPheHisAla:	AsplleCust	hrtauSarG1	uTueGlubea	Clatiatus
	AAAGAG	TTAATGCTG	AAACATTCAC	CTTCCATGCA	CATATATGCA	CACTTTCTCA	CAACCACACA	CANATCANG
	6		1596		1616		1636	1646
						1020	1030	1040
	LysGln?	ThrAlaLeuV	alGluLeuVal	lLvsHisLvsI	ProLvsAlaT	hrLvsGluGl	nLeuLvsAla'	ValMetAsn
	AAACAA	ACTGCACTTG	TTGAGCTTGT	GAAACACAAG	CCAAGGCAA	CAAAAGAGCA	ACTGAAAGCT	GTTATGGAT
165		1661	1671	1681	1691	1701	1711	1721
	AspPhel	AlaAlaPheV	alGluLysCys	sCysLysAla	AspAspLysG	luThrCysPh	eAlaGluGlu	GlyLysLys
	GATTTC	GCAGCTTTTG'	TAGAGAAGTG(	CTGCAAGGCT	GACGATAAGG	AGACCTGCTT	TGCCGAGGAG	GGTAAAAAA
172	6	1736	1746	1756	1766	1776	1786	1796
	LeuVal	AlaAlaSerG	lnAlaAlaLe	ıGlyLeuLys1	LysValValL	euGlyLysLy	sGlyAspThr'	ValGluLeu
			AAGCTG <u>CCTT</u>				AGGGGATACA	GTGGAACTG
180	1	1811	1821	1831	1841	1851	1861	1871
	ThrCys:	ThrAlaSerG	lnLysLysSe	rIleGlnPhe	HisTrpLysA:	snSerAsnGl	nIleLysIle	LeuGlyAsn
187	ACCTGT/		agaāgaāgag(					
18/	6	1886	1896	1906	1916	1926	1936	1946
	G1 nG1+4	Samphal aum	hrLysGlyPro	Control on				
	CACCCC	CCTTCTTAA	CTAAAGGTCC	races section	ASHASPAEGA.	raaspserar	gargserteu	TrpAspGin
195	44666C.	1961	1971	1981	1991	2001	AAGAAGCCTT 2011	2021
- / /	•	1301	13/1	1901	1331	2001	2011	2021
	GlvAsni	PheProTenT	leIleLysAsı	nT.enT.veTle/	Il IIA engara	sከጥክ ታጥላ ታቸ <sup>1</sup>	eCveCl vVal	Gluaencle
	GGAAAC'	TCCCCCTGA	ICATCAAGAA:	CTTAAGATA	GAAGACTCAG	ATACTTACAT	CTGTGAAGTG	GYCCYCCYC GYMYSDGYII
202	6	2036	2046	2056	2066	2076	2086	2096
								2070
	LysGlu	GluValGlnL	euLeuValPhe	eGlyLeuThr	AlaAsnSerA:	spThrHisLe	uLeuGlnGl v	GlnSerLeu
	AAGGAG	GAGGTGCAAT	TGCTAGTGTT	CGGATTGACT	CCAACTCTG	ACACCCACCT	GCTTCAGGGG	CAGAGCCTG
210						2151	21.61	2171

ThrLeuThrLeuGluSerProProGlySerSerProSerValGlnCysArgSerProArgGlyLysAsnileGln ACCCTGACCTTGGAGAGCCCCCCTGGTAGTAGCCCCCTCAGTGCAATGTAGGAGTCCAAGGGGTAAAAACATACAG 2176 2186 2196 2206 2216 2226 2236 2246

GlyGlyLysThrLeuSerValSerGlnLeuGluLeuGlnAspSerGlyThrTrpThrCysThrValLeuGlnAsn GGGGGGGAAGACCCTCTCCGTGTCTCAGCTGGAGCTCCAGGATAGTGGCACCTGGACATGCACTGTCTTGCAGAAC 2251 2261 2271 2281 2291 2301 2311 2321

GlnLysLysValGluPheLysIleAspIleValValLeuAlaPhe\*\*\*
CAGAAGAAGGTGGAGTTCAAAAATAGACATCGTGGTGCTAGCTTTCTAAAAGCTT
2326 2336 2346 2356 2366 2376




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18





Figure 19






Figure 20




Figure 21




Figure 22A




Figure 22B

# INHIBITION OF INFECTION




Figure 23




Figure 24




Figure 25




Figure 26




Figure 27




Figure 28




Figure 29




Figure 30




Figure 31




Figure 32






Figure 33









Figure 35








Figure 36











Figure 37






Figure 38